How To Use HCPCS Code C9898

HCPCS code C9898 describes a radiolabeled product that is provided during a hospital inpatient stay. This code is used to identify a parenteral supply that is not otherwise classified. It falls under the category of special coverage instructions, denoted by the coverage code D. The code does not require any maintenance and has been in effect since January 01, 1996. It was added to the Healthcare Common Procedure Coding System on January 01, 1985. The pricing indicator code for this code is 57, indicating that it is priced by other carriers. The multiple pricing indicator code is A, which means it is not applicable as HCPCS is priced under one methodology. The code is referenced in the Medicare Carriers Manual under section number 2130. The type of service code for C9898 is E, which stands for enteral/parenteral nutrients/supplies, effective from April 1995. The anesthesia base unit quantity for this code is 0.

1. What is HCPCS C9898?

HCPCS code C9898 is used to identify a radiolabeled product that is provided during a hospital inpatient stay. It is specifically used to classify a parenteral supply that does not fall under any other category. This code is essential for accurate medical coding and billing processes.

2. Official Description

The official description of HCPCS code C9898 is “Radiolabeled product provided during a hospital inpatient stay.” The short description for this code is “Parenteral supp not othrws c.”

3. Procedure

1. When administering the radiolabeled product, ensure that it is provided during a hospital inpatient stay.
2. Follow the appropriate protocols and guidelines for handling and administering radiolabeled products.
3. Ensure that the product is administered parenterally, meaning it is delivered through a route other than the digestive tract.
4. Document the administration of the radiolabeled product accurately and thoroughly.

4. When to use HCPCS code C9898

HCPCS code C9898 should be used when a radiolabeled product is provided to a patient during their hospital inpatient stay. It is important to ensure that the product meets the criteria specified in the code description. This code should not be used for any other type of parenteral supply or in outpatient settings.

5. Billing Guidelines and Documentation Requirements

When billing for HCPCS code C9898, healthcare providers need to ensure that they accurately document the administration of the radiolabeled product during a hospital inpatient stay. The documentation should include details such as the date and time of administration, the specific product used, and any relevant patient information. It is also important to follow the billing guidelines set forth by the payer, ensuring that all necessary information is included on the claim form.

6. Historical Information and Code Maintenance

HCPCS code C9898 was added to the Healthcare Common Procedure Coding System on January 01, 1985. It has an effective date of January 01, 1996, and has not undergone any maintenance actions since its addition. The action code N indicates that no maintenance is required for this code. It is important to stay updated with any changes or revisions to the code to ensure accurate coding and billing practices.

7. Medicare and Insurance Coverage

Medicare and other insurance providers may cover the radiolabeled product provided during a hospital inpatient stay, as indicated by the special coverage instructions denoted by the coverage code D. The pricing indicator code 57 suggests that the pricing for this code is determined by other carriers. The multiple pricing indicator code A indicates that the code is not applicable as HCPCS is priced under one methodology. It is important to verify coverage and pricing with the specific payer to ensure accurate reimbursement.

8. Examples

Here are five examples of when HCPCS code C9898 should be billed:

1. A patient undergoes a radiolabeled product administration during their hospital inpatient stay for diagnostic imaging purposes.
2. A radiolabeled product is provided to a patient during their hospital inpatient stay as part of a therapeutic treatment plan.
3. A radiolabeled product is administered to a patient during their hospital inpatient stay to monitor the progress of a specific condition.
4. A radiolabeled product is used during a hospital inpatient stay to assist in the localization of a tumor or abnormality.
5. A radiolabeled product is administered to a patient during their hospital inpatient stay to evaluate the function of a specific organ or system.